Additional file 3 of The MYC/TXNIP axis mediates NCL-Suppressed CD8+T cell immune response in lung adenocarcinoma

Supplementary Material 3: Figure S3. Comparative Prognostic Value of GPLD1 and NCL. Notes: (A-B) The expression levels of GPLD1 (A) and NCL (B) in normal lung tissues and tumor tissues of Lung adenocarcinoma patients (Normal group, N = 59; Tumor group, N = 539); (C-D) Showing the ROC curves for predicting the survival status of Lung adenocarcinoma patients with GPLD1 (C) and NCL (D) (N = 522); (E) AUC for predicting 1-10-year survival rates of Lung adenocarcinoma patients using GPLD1 and NCL (N = 522); (F-G) Distribution of GPLD1 (F) and NCL (G) in the single-cell atlas; (H-J) Survival curves for Overall Survival (H), Disease-Specific Survival (I), and Progress-Free Interval (J) in patients with high and low GPLD1 expression levels (N = 522); *** indicates statistical significance at P <.